Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.

Details

Ressource 1Download: 29969256_pp_cover.pdf (1902.44 [Ko])
State: Public
Version: Author's accepted manuscript
License: Not specified
Serval ID
serval:BIB_7742B6947DD4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.
Journal
Journal of medicinal chemistry
Author(s)
Juillerat-Jeanneret L., Aubert J.D., Mikulic J., Golshayan D.
ISSN
1520-4804 (Electronic)
ISSN-L
0022-2623
Publication state
Published
Issued date
21/11/2018
Peer-reviewed
Oui
Volume
61
Number
22
Pages
9811-9840
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Fibrosis is an inadequate response to tissue stress with very few therapeutic options to prevent its progression to organ dysfunction. There is an urgent need to identify drugs with a therapeutic potential for fibrosis, either by designing and developing new compounds or by repurposing drugs already in clinical use which were developed for other indications. In this Perspective, we summarize some pathways and biological targets involved in fibrosis development and maintenance, focusing on common mechanisms between organs and diseases. We review the therapeutic agents under experimental development, clinical trials, or in clinical use for the treatment of fibrotic disorders, evaluating the reasons for the discrepancies observed between preclinical and clinical results. We also discuss the improvement that we envision in the development of therapeutic molecules able to achieve improved potential for treatment, including indirect modulators, targeting approaches, or drug combinations.
Keywords
Animals, Drug Discovery, Fibrosis/drug therapy, Fibrosis/metabolism, Fibrosis/pathology, Humans, Molecular Targeted Therapy, Organ Specificity
Pubmed
Web of science
Create date
19/10/2018 9:20
Last modification date
04/10/2019 5:09
Usage data